VanEck Associates
RARE icon

VanEck Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

VanEck Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91K Sell
4,357
-810
-16% -$18.2K ﹤0.01% 1309
2025
Q4 		$119K Buy
5,167
+2,517
+95% +$82.8K ﹤0.01% 1315
2025
Q3 		$80K Buy
2,650
+549
+26% +$16.5K ﹤0.01% 1332
2025
Q2 		$76K Buy
2,101
+308
+17% +$11.1K ﹤0.01% 1313
2025
Q1 		$65K Buy
1,793
+33
+2% +$1.37K ﹤0.01% 1297
2024
Q4 		$74K Buy
1,760
+273
+18% +$13.5K ﹤0.01% 1283
2024
Q3 		$81K Sell
1,487
-457
-24% -$23.3K ﹤0.01% 1261
2024
Q2 		$80K Buy
1,944
+36
+2% +$1.54K ﹤0.01% 1264
2024
Q1 		$89K Buy
1,908
+330
+21% +$15.6K ﹤0.01% 1241
2023
Q4 		$75K Buy
1,578
+400
+34% +$15.5K ﹤0.01% 1261
2023
Q3 		$42K Buy
1,178
+29
+3% +$1.15K ﹤0.01% 1296
2023
Q2 		$53K Buy
+1,149
New +$53.3K ﹤0.01% 1300

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VanEck Associates's RARE Position: Q1 2026 in Review

VanEck Associates reduced its Ultragenyx Pharmaceutical (RARE) stake by 16% in Q1 2026, selling an estimated $18.2K and leaving 4,357 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #1309.

VanEck Associates first reported a position in RARE in Q2 2023 and has held it in 12 quarters since. The position peaked at $119K in Q4 2025. 297 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • VanEck Associates held 4,357 shares of Ultragenyx Pharmaceutical worth $91K as of Q1 2026.
  • VanEck Associates sold 810 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $18.2K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #1309 holding.
  • VanEck Associates first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 12 quarters since.
  • VanEck Associates's Ultragenyx Pharmaceutical position peaked at $119K in Q4 2025.
  • 297 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.